Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT06660680

The Effect of Methylene Blue Infiltrating Injection on Anal Pain After Milligan-Morgan Surgery: A Randomized Controlled Clinical Study

the Ethics Committee of the Second Hospital of Chinese Medicine

Status
Enrolling By Invitation
Phase
Phase 3
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

A variety of analgesic strategies are available following mixed hemorrhoids surgery, including pharmacological interventions (7), acupuncture, moxibustion, and electroacupuncture . Medications such as opioid analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used but can be associated with side effects including nausea, vomiting, and gastrointestinal bleeding, with long-term use potentially leading to addiction (8). Complementary therapies require skilled administration and regular treatment sessions. Methylene blue (MB), a cationic thiazine dye extensively utilized as a biological stain and chemical indicator, has been increasingly recognized for its potential analgesic properties (9). In the present study, methylene blue infiltrating injection (MBI) was administered to treat anal pain resulting from Milligan-Morgan surgery, with the aim of assessing its analgesic efficacy and safety profile.

Conditions

Interventions

TypeNameDescription
DRUGMethylene BlueReceived MBI treatment to their surgical incisions upon completion of surgery

Timeline

Start date
2024-10-25
Primary completion
2025-10-01
Completion
2025-10-01
First posted
2024-10-28
Last updated
2024-10-28

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06660680. Inclusion in this directory is not an endorsement.

The Effect of Methylene Blue Infiltrating Injection on Anal Pain After Milligan-Morgan Surgery: A Randomized Controlled (NCT06660680) · Clinical Trials Directory